跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-22AI 评分31

Rezera 提交 IPO 申请以支持 NLRP3 在周围动脉疾病领域的研发

Rezera files for IPO to back NLRP3 work in peripheral artery disease

AI 导读

Rezera(前 NodThera)已进入 IPO 排队阶段,旨在为其十年期 NLRP3 项目提供资金。该管线针对周围动脉疾病,目前仍处于申报阶段,尚未上市。

正文

Rez­era, the biotech that re­brand­ed from NodThera ear­li­er this year, has en­tered the queue for an ini­tial pub­lic of­fer­ing to bol­ster its decade-long NL­RP3 ef­forts.

…

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news